About Geniron Biolabs
Geniron Biolabs was a Healthcare company based in Bengaluru (India) founded in 2013 by Goutham G. It develops vaccines, diagnostics, and nutraceuticals to enhance animal health and well-being. It operates on a B2B model. Its Indian entity Geniron Biolabs Private Limited reported revenue of ₹1.43 Cr. The company is recorded as dissolved. Its focus areas include Biotechnology, Animal Health and Vaccines and Diagnostics. Its competitors include Sino Biological, GenScript, Mabtech, Y-Biologics and Epitomics and 5 more; 5 of its 10 listed competitors have raised funding.
Company details
Geniron Biolabs develops vaccines, diagnostics, and nutraceuticals to enhance animal health and well-being, focusing on providing healthcare solutions, advancing biotech innovations, focusing on animal health, and vaccines and diagnostics. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets.
- Headquarters Bengaluru, India
- Founders Goutham G
- SectorsHealthcare
- Website geniron.in
- Legal Name Geniron Biolabs Private Limited
- Date of Incorporation 02 Apr, 2013
- Jurisdiction Bangalore, Karnataka, India
- Annual Revenue₹1.43 Cr
FY 2018 · -4% YoY
- Net Profit₹3.9 Lakh
FY 2018 · 3% margin
- EBITDA₹8 Lakh
FY 2018 · 6% margin
- InvestorsStartup Karnataka
& 1 more
Associated legal entities of Geniron Biolabs
Geniron Biolabs operates through Geniron Biolabs Private Limited (strike off). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2018) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Geniron Biolabs Private Limited CIN U93000KA2013PTC068405 | Strike Off | 02 Apr 2013 | Bangalore, Karnataka | ₹1.4 Cr | – | 2 | View details |
Funding Insights of Geniron Biolabs
- Total Rounds 2
- Investors Count 2
All 2 funding rounds of Geniron Biolabs with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2018 | – | Grant | – | – | |
| Jun 2015 | – | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Geniron Biolabs
Geniron Biolabs has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Startup Karnataka and Department of Biotechnology.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Support for startups in Karnataka is delivered through policies, funding, and networking services. | 2004 | missionstartupkarnataka.org | Bengaluru, India | |
Biotechnology research, guidelines, and funding by the Government of India. | 1986 | dbtindia.gov.in | Delhi, India |
Investor details for Geniron Biolabs
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Geniron Biolabs Private Limited (Geniron Biolabs)
Geniron Biolabs Private Limited is the primary company behind Geniron Biolabs. The board of Geniron Biolabs Private Limited currently have 2 directors; the longest-serving is Goutham Govindaraju, appointed in 2013. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Goutham Govindaraju DIN 06490534 | Director | 02 Apr 2013 | 13 yrs 6 mo | Geniron Biolabs Private Limited |
| Shruthi Vinayakumar DIN 07792239 | Additional Director | 04 Jul 2019 | 7 yrs 3 mo | Geniron Biolabs Private Limited |
People of Geniron Biolabs
1 people are tracked at Geniron Biolabs (1 in leadership).
| Name | Role | Group |
|---|---|---|
Goutham G | Founder | Leadership |
Complete people profiles for Geniron Biolabs
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Geniron Biolabs
Figures of Geniron Biolabs Private Limited, the primary company behind Geniron Biolabs, for FY 2018. Revenue was ₹1.43 Cr (-4% year on year). Net profit was ₹3.9 Lakh (3% margin). EBITDA was ₹8 Lakh (6% margin). Revenue has grown at a compounded annual rate of +92% over three years.
- ₹1.43 CrRevenue · FY 2018 · -4% YoY
- ₹3.9 LakhNet profit · 3% margin
- ₹8 LakhEBITDA · 6% margin
- ₹1 LakhPaid-up capital
- +92%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Geniron Biolabs Private Limited are on its company page.
Detailed financial statements for Geniron Biolabs
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Geniron Biolabs
3 dated milestones of Geniron Biolabs across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Geniron Biolabs is founded.
- Funding First funding round.
- Funding Latest funding round, Grant,.
Competitors of Geniron Biolabs
Geniron Biolabs has 10 listed competitors in our database, 5 of them funded. They include Sino Biological, GenScript, Mabtech, Y-Biologics and Epitomics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sinobiological.com | 2007 | Beijing, China | $29.41M | – | Reagents and kits are provided for clinical research applications. | |
| genscript.com | 2002 | Piscataway, United States | $15M | 5,260 | Reagents and instruments are provided for life sciences research. | |
| mabtech.com | 1986 | Nacka, Sweden | – | – | Antibodies and immunoassay kits are developed for research applications. | |
| ybiologics.com | 2007 | Daejeon, South Korea | $42.1M | – | Developer of antibodies for the treatment of multiple diseases | |
| epitomics.com | 2001 | Burlingame, United States | $16.21M | – | Monoclonal antibody technology and products are developed by Epitomics. | |
| opmbiosciences.com | 2013 | Pudong, China | $14.42M | – | Antibody and vaccine culture media products are developed. | |
| vectorlabs.com | 1976 | Burlingame, United States | – | – | Labeling and detection reagents immunohistochemistry studies and other life science research applications | |
| leinco.com | 1992 | St. Louis, United States | – | – | Manufacturer of antibodies, proteins, reagents, and kits for life science research | |
| icosagen.com | 2005 | Tartu, Estonia | – | – | Services in custom antibody and protein production are provided. | |
| bioventix.com | 2003 | Farnham, United Kingdom | – | 16 | Sheep monoclonal antibody manufacturer |
Detailed competitors of Geniron Biolabs
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
10 companies that operate in the same segment as Geniron Biolabs (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Geniron Biolabs
Geniron Biolabs was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Geniron Biolabs is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
The primary company behind Geniron Biolabs, Geniron Biolabs Private Limited, reported revenue of ₹1.43 Cr for FY 2018, down 4% year on year.
Geniron Biolabs develops vaccines, diagnostics, and nutraceuticals to enhance animal health and well-being, focusing on providing healthcare solutions, advancing biotech innovations, focusing on animal health, and vaccines and diagnostics. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets.
Geniron Biolabs's top competitors include Sino Biological, GenScript and Y-Biologics.
Geniron Biolabs has 2 investors. Key investors include Startup Karnataka, and Department of Biotechnology.
Geniron Biolabs operates through Geniron Biolabs Private Limited.
The legal entities of Geniron Biolabs currently have 2 directors, including Shruthi Vinayakumar, Goutham Govindaraju.